 SYDNEY, July 21, 2021 PRNewswire -- Kazia Therapeutics Limited NASDAQ: KZIA; ASX: KZA, a leading drug development company in the field of brain cancer, today recognizes Glioblastoma GBM Awareness Day and calls for a greater focus on research from industry, academia, and government in order to better treat the disease. GBM is the most common and most aggressive form of primary brain cancer, and it is expected that approximately 13,000 Americans will receive a GBM diagnosis in 2021. 